Tuesday, July 9, 2019

Metastatic prostate cancer, or prostate cancer that has spread to other organs, is incurable. In new research published in the journal Science, Roswell Park Cancer Institute scientists have identified two gatekeeper genes that allow prostate cancer to progress and resist treatment. Their work illuminates the mechanisms behind lineage plasticity, the ability of prostate cancer to adapt to therapy, and highlights opportunities to disrupt and even reverse this deadly process.
"Androgen-deprivation therapy is commonly used to treat patients whose prostate cancer has spread beyond the prostate. While most men initially respond to this therapy, the cancer nearly always returns and is often aggressive and lethal. We have discovered a mechanism that causes progression to this aggressive form of prostate cancer, providing a new opportunity to prevent or treat lethal forms of prostate cancer," says co-senior author David Goodrich, PhD, Professor of Oncology in the Department of Pharmacology and Therapeutics at Roswell Park.
"Importantly, these findings offer a new understanding of prostate cancer lineage plasticity, which involves the conversion of cancer cells that are dependent on a specific therapeutic target to cancer cells that are now indifferent to that target's function," adds co-senior author Leigh Ellis, PhD, Assistant Professor of Oncology in the Department of Pharmacology and Therapeutics. "This discovery offers the possibility to reverse or delay lineage plasticity, thereby prolonging the effectiveness of the currently used therapies, like androgen deprivation. And this new understanding has the potential to be applicable in other types of cancers."
Using preclinical models, the scientists demonstrated that loss of the tumor-suppressor gene known as Rb1 induces lineage plasticity and metastatic progression of prostate cancer. They also show that increased expression of another gene, Ezh2, is associated with lineage plasticity and may be therapeutically exploited. Treatment of resistant tumors with drugs that inhibit the Ezh2 gene may resensitize prostate cancer to androgen-deprivation therapy. The team expects to pursue these findings further in clinical studies at Roswell Park.

Friday, June 21, 2019

For the vast majority of cancer drugs experiencing shortages over a seven-year period, a new USC research study found no statistically significant effect of shortages on chemotherapy treatment.
"These findings are surprising in light of the substantial media and policy attention that the cancer drug shortage problem has garnered," said Mireille Jacobson, study coauthor and associate professor of gerontology at the USC Leonard Davis School and the Schaeffer Center for Health Policy & Economics.
Although the proportion of patients receiving treatment declined for six drugs, including fluorouracil, doxorubicin, and cytarabine, the use of 32 other cancer drugs was unaffected or even increased during shortage episodes. Likewise, dosages declined for only a few drugs during shortages. The results were published April 8 in Clinical Pharmacology & Therapeutics.
Researchers noted that while the shortages may not have been noticeable from a treatment perspective, they may have come at personnel and psychic costs not measured by the study. "This study only measured one dimension of oncology drug shortages: the effect on utilization," said Jacobson.

Increasing oncology drug shortages raised alarms

The number of prescription drug shortages in the United States increased from 71 in 2005 to 255 in 2011, and shortages of oncology drugs more than doubled during that time period. Oncology drug shortages in particular have generated substantial attention from the media and policymakers because of concerns about treatment gaps and inadequate dosing. For cancers in which certain treatments are clinically preferred or no alternative exists, drug shortages may be life-threatening.
Until now, no studies have systematically analyzed the consequences of shortages nationwide. Using data from the Surveillance, Epidemiology, and End Results (SEER) cancer registries linked with Medicare claims, Jacobson and colleague Abby Alpert with the University of Pennsylvania set out to provide a more general analysis of the impact of oncology drug shortages on outpatient chemotherapy treatment.

**Come and Join us at Pharma Forum 2019 https://pharmacology.healthconferences.org/ 

Monday, June 17, 2019

Pharma Forum 2019

About Conference


Global Congress on Pharmacology and Therapeutics scheduled during October 07-08, 2019 in Paris, France. This Conference focusses on the theme “Exploring new Pharmacological Principles for better health care.”
Conference Series LLC Ltd amiably invites the pharmacologists, Therapeutic Professionals, academicians, professionals to Pharma Forum 2019. This Scientific gathering offers a unique platform to present and know the latest updates with a complete approach to diverse areas of therapeutic interest. Therapeutic studies starts right from the preclinical drug development and ends with the post marketing surveillance. These studies are supported by advanced techniques such as diagnostic imaging, toxicological studies.Pharma Forum 2019 is organized with an added focus on the application of pharmacological principles and quantitative methods in the real human patient's population to improve the health care.Pharmacologists have access to enough outpatients for clinical care. Their responsibilities to patients are not only restricted to the analysis of adverse drug effects, therapeutics and toxicology but also includes the study of cardiovascular risks, perioperative drug management and psychopharmacology.

Why Pharma Forum 2019?
Global Congress on Pharmacology and Therapeutics Conference provides an optimistic platform for exchanging ideas and helps the attendees to get updated about the advancements and innovations in therapeutics and Pharmacology. The conference regular scientific sessions will be followed by exhibition, workshops and sessions of Networking.We hope this Congress provides an excellent opportunity to share your best practice initiative, research project, or provide continuing education as it relates current topics and advances around the industries and field of pharmaceutical and therapeutic research. Pharma Forum 2019 provides participants breakout sessions highlighting clinical projects, education, and research studies. This conference also includes interactive sessions and keynote panel discussions.


Conference Highlights
  • Pharmacology
  • Cardiovascular Pharmacology
  • Clinical Pharmacology and Receptor Therapy
  • Neuropharmacology
  • Psychopharmacology
  • Pediatric Pharmacology
  • Occular Pharmacology
  • Immuno Pharmacology
  • Nursing Pharmacology
  • Molecular Pharmacology
  • Pharmacological Testing
  • Pharmacokinetics and Pharmacodynamics
  • Advances in Pharmacological Research
  • Ethnopharmacology and Ethnomedicine
  • Toxicology
  • Pharmacogenetics and Pharmacogenomics
  • Pharmacology and Drug Design
  • Clinical Therapeutics
  • Cognitive Behavior Therapy
  • Holistic Therapy

Special Issues

 - All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.
 - Abstracts will be provided with Digital Object Identifier by Cross Ref.

  See more at
https://pharmacology.healthconferences.org/